Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic

Rachel B Issaka, Preston Taylor, Anand Baxi, John M Inadomi, Scott D Ramsey, Joshua Roth, Rachel B Issaka, Preston Taylor, Anand Baxi, John M Inadomi, Scott D Ramsey, Joshua Roth

Abstract

Importance: COVID-19 has decreased colorectal cancer screenings.

Objective: To estimate the degree to which expanding fecal immunochemical test-based colorectal cancer screening participation during the COVID-19 pandemic is associated with clinical outcomes.

Design, setting, and participants: A previously developed simulation model was adopted to estimate how much COVID-19 may have contributed to colorectal cancer outcomes. The model included the US population estimated to have completed colorectal cancer screening pre-COVID-19 according the American Cancer Society. The model was designed to estimate colorectal cancer outcomes between 2020 and 2023. This analysis was completed between July and December 2020.

Exposures: Adults screened for colorectal cancer and colorectal cancer cases detected by stage.

Main outcomes and measures: Estimates of colorectal cancer outcomes across 4 scenarios: (1) 9 months of 50% colorectal cancer screenings followed by 21 months of 75% colorectal cancer screenings; (2) 18 months of 50% screening followed by 12 months of 75% screening; (3) scenario 1 with increased use of fecal immunochemical tests; and (4) scenario 2 with increased use of fecal immunochemical tests.

Results: In our simulation model, COVID-19-related reductions in care utilization resulted in an estimated 1 176 942 to 2 014 164 fewer colorectal cancer screenings, 8346 to 12 894 fewer colorectal cancer diagnoses, and 6113 to 9301 fewer early-stage colorectal cancer diagnoses between 2020 and 2023. With an abbreviated period of reduced colorectal cancer screenings, increasing fecal immunochemical test use was associated with an estimated additional 588 844 colorectal cancer screenings and 2836 colorectal cancer diagnoses, of which 1953 (68.9%) were early stage. In the event of a prolonged period of reduced colorectal cancer screenings, increasing fecal immunochemical test use was associated with an estimated additional 655 825 colorectal cancer screenings and 2715 colorectal cancer diagnoses, of which 1944 (71.6%) were early stage.

Conclusions and relevance: These results suggest that the increased use of fecal immunochemical tests during the COVID-19 pandemic was associated with increased colorectal cancer screening participation and more colorectal cancer diagnoses at earlier stages. If our estimates are borne out in real-world clinical practice, increasing fecal immunochemical test-based colorectal cancer screening participation during the COVID-19 pandemic could mitigate the consequences of reduced screening rates during the pandemic for colorectal cancer outcomes.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ramsey reported receiving consulting fees from Epigenomics as an advisor outside the submitted work. No other disclosures were reported.

Figures

Figure 1.. Schematic of Modeled COVID-19 Scenarios
Figure 1.. Schematic of Modeled COVID-19 Scenarios
Figure 2.. Baseline Screening Population
Figure 2.. Baseline Screening Population

References

    1. Siegel RL, Miller KD, Goding Sauer A, et al. . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164. doi:10.3322/caac.21601
    1. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med. 2010;7(11):e1000370. doi:10.1371/journal.pmed.1000370
    1. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1-8. doi:10.7326/0003-4819-150-1-200901060-00306
    1. Mandel JS, Bond JH, Church TR, et al. ; Minnesota Colon Cancer Control Study . Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328(19):1365-1371. doi:10.1056/NEJM199305133281901
    1. Cyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. Am J Manag Care. 2016;22(2):105-111.
    1. American Cancer Society . Colorectal Cancer Facts & Figures 2020-2022. American Cancer Society; 2020.
    1. National Colorectal Cancer Roundtable . Colorectal cancer screening rates reach 44.1% in FQHCs in 2018. Published 2020. Accessed August 20, 2020.
    1. National Colorectal Cancer Roundtable . 80% in every community. Published 2019. Accessed January 15, 2020.
    1. Centers for Medicare & Medicaid Services . CMS adult elective surgery and procedures recommendations. Published 2020. Accessed March 23, 2020.
    1. Periyanaayagam U, Dwter A, Kim J, Garcia R, Worrall S, Davis A. New colorectal cancer diagnoses fall by one-third as colonoscopy screenings and biopsies grind to a halt during height of COVID-19. Fight Colorectal Cancer . Published May 2020. Accessed November 1, 2020.
    1. Martin K, Kurowski D, Given P, Kennedy K, Clayton E. The impact of COVID-19 on the use of preventive health care. Health Care Cost Institute . Published 2020. Updated September 9, 2020. Accessed June 21, 2020.
    1. Joseph DA, King JB, Richards TB, Thomas CC, Richardson LC. Use of colorectal cancer screening tests by state. Prev Chronic Dis. 2018;15:E80. doi:10.5888/pcd15.170535
    1. Levin TR, Corley DA, Jensen CD, et al. . Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383-1391.e5. doi:10.1053/j.gastro.2018.07.017
    1. Inadomi JM, Vijan S, Janz NK, et al. . Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582. doi:10.1001/archinternmed.2012.332
    1. Inadomi JM. Screening for colorectal neoplasia. N Engl J Med. 2017;376(16):1599-1600.
    1. Gupta S, Coronado GD, Argenbright K, et al. . Mailed fecal immunochemical test outreach for colorectal cancer screening: summary of a Centers for Disease Control–sponsored summit. CA Cancer J Clin. 2020;70(4):283-298. doi:10.3322/caac.21615
    1. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171. doi:10.7326/M13-1484
    1. Roth JA, deVos T, Ramsey SD. Clinical and budget impact of increasing colorectal cancer screening by blood- and stool-based testing. Am Health Drug Benefits. 2019;12(5):256-262.
    1. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. ; US Preventive Services Task Force . Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989
    1. Sullivan SD, Mauskopf JA, Augustovski F, et al. . Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5-14. doi:10.1016/j.jval.2013.08.2291
    1. Knudsen AB, Zauber AG, Rutter CM, et al. . Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315(23):2595-2609. doi:10.1001/jama.2016.6828
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;371(2):187-188. doi:10.1056/NEJMoa1311194
    1. Johnson DA, Barclay RL, Mergener K, et al. . Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014;9(6):e98238. doi:10.1371/journal.pone.0098238
    1. Liles EG, Perrin N, Rosales AG, et al. . Change to FIT increased CRC screening rates: evaluation of a US screening outreach program. Am J Manag Care. 2012;18(10):588-595.
    1. Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? a comparison of costs, effectiveness, and compliance. Am J Med. 2001;111(8):593-601. doi:10.1016/S0002-9343(01)00977-9
    1. Church TR, Wandell M, Lofton-Day C, et al. ; PRESEPT Clinical Study Steering Committee, Investigators and Study Team . Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317-325. doi:10.1136/gutjnl-2012-304149
    1. Ferlitsch M, Reinhart K, Pramhas S, et al. . Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA. 2011;306(12):1352-1358. doi:10.1001/jama.2011.1362
    1. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284(15):1954-1961. doi:10.1001/jama.284.15.1954
    1. Somsouk M, Rachocki C, Mannalithara A, et al. . Effectiveness and cost of organized outreach for colorectal cancer screening: a randomized, controlled trial. J Natl Cancer Inst. 2020;112(3):305-313. doi:10.1093/jnci/djz110
    1. Sharpless NE. COVID-19 and cancer. Science. 2020;368(6497):1290. doi:10.1126/science.abd3377
    1. Issaka RB, Somsouk M. Colorectal cancer screening and prevention in the COVID-19 era. JAMA Health Forum. Posted May 13, 2020. Accessed March 9, 2021.
    1. Issaka RB, Avila P, Whitaker E, Bent S, Somsouk M. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: a systematic review. Prev Med. 2019;118:113-121. doi:10.1016/j.ypmed.2018.10.021
    1. Ricciardiello L, Ferrari C, Cameletti M, et al. . Impact of SARS-CoV-2 pandemic on colorectal cancer screening delay: effect on stage shift and increased mortality. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)31236-2. doi:10.1016/j.cgh.2020.09.008
    1. Maringe C, Spicer J, Morris M, et al. . The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034. doi:10.1016/S1470-2045(20)30388-0
    1. Loveday C, Sud A, Jones ME, et al. . Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Gut. Published online August 27, 2020. doi:10.1136/gutjnl-2020-321650
    1. Robertson DJ, Kaminski MF, Bretthauer M. Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. Gut. 2015;64(6):982-990. doi:10.1136/gutjnl-2014-308076
    1. Hamel L, Kirzinger A, Lopes L, Kearney A, Sparks G, Brodie M. KFF COVID-19 Vaccine Monitor: January 2021. Updated January 22, 2021. Accessed January 31, 2021.
    1. Chubak J, Garcia MP, Burnett-Hartman AN, et al. ; PROSPR consortium . Time to colonoscopy after positive fecal blood test in four U.S. health care systems. Cancer Epidemiol Biomarkers Prev. 2016;25(2):344-350. doi:10.1158/1055-9965.EPI-15-0470
    1. Issaka RB, Singh MH, Oshima SM, et al. . Inadequate utilization of diagnostic colonoscopy following abnormal FIT results in an integrated safety-net system. Am J Gastroenterol. 2017;112(2):375-382. doi:10.1038/ajg.2016.555
    1. Issaka RB, Akinsoto NO, Strait E, Chaudhari V, Flum DR, Inadomi JM. Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. Therap Adv Gastroenterol. 2020;13:1756284820945388. doi:10.1177/1756284820945388

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir